New Alert: Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Last Close: $2.94

Good Morning Member,


Citius Pharmaceuticals, Inc. (CTXR) is our new Nasdaq alert and we believe this company has great potential in the biotech space.


CTXR is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets.


Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development. Citius is currently advancing two proprietary product candidates, their Mino-Lok™ product and a Hydrocortisone-Lidocaine (Hydro-Lido) formulation. The company believes the markets for its products are large and underserved by the current standard of care.


Lets take a look below at CTXR’s proprietary product candidates.




CTXR’s Mino-Lok™ product, developed by clinicians and technologists at the M.D. Anderson Cancer Center, could provide a superior alternative to removing and replacing central venous catheters (CVCs). Of the approximately 7 million CVCs used annually, about 500,000 or 7% become contaminated leading to serious, life threatening infections called catheter-related blood stream infections (CRBSIs).


A 90 patient Phase 2b clinical study using their Mino-Lok™ product demonstrated sufficient safety to proceed to a pivotal Phase 3 trial. Based on Phase 2b results, Citius believes that their Mino-Lok™ product is highly effective in salvaging infected indwelling catheters and is well tolerated, making Mino-Lok™ therapy an attractive alternative to removing and re-inserting a new CVC. CTXR plans to conduct a Phase 3, multi-center, randomized, double blind, placebo- and active- controlled study in 700 patients.


In addition, their Mino-Lok™ product has received a U.S. FDA Qualified Infectious Disease Product (QIDP) designation. Receiving QIDP designation means that Mino-Lok™ is eligible for Fast Track designation, Priority Review for development, and a five-year extension of market exclusivity. Learn More about Mino-Lok™ Here.




Hydro-Lido is a topical formulation of hydrocortisone and lidocaine that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. In the United States, hemorrhoids affect nearly 5% of the population, with approximately 10 million patients annually reporting symptoms of hemorrhoidal disease; approximately one-third visit a physician for evaluation and treatment of their hemorrhoids. Citius has recently completed Phase 2a studies for its hydrocortisone-lidocaine topical therapy.


Citius believes their hydrocortisone and lidocaine formulation could become the first FDA-approved product to treat hemorrhoids in the United States. According to IMS, over 25M units of topical combination prescription products for hemorrhoids were sold in the United States during the twelve-month period ended June 2012, comprising an estimated $80M annual market. Learn More about Hydro-Lido Here.


CTXR has a pipeline portfolio of important, high potential, later stage drugs that address unmet medical needs and are in progressive stages. CTXR also has a highly experienced and successful management team with extensive experience building and managing pharmaceutical companies and creating significant shareholder value.


CTXR has also had positive recent developments including a Phase 3 update on their Mino-Lok™ product following an FDA Meeting. Read all of the recent news below.


Recent News




Highlights of the letter to shareholders include:


  • CTXR has recently and successfully uplisted to Nasdaq stock exchange where the company will gain access to broader investor audience.
  • The company received a positive response from the U.S. Food and Drug Administration (FDA) for phase 3 trial amendments of Mino-Lok™, their proprietary product that address a potential $750M sector.
  • Secured funding of more than $26.8M, including a recent raise of $6.8M, with significant insider participation.
  • Finalized the addition of South America to The Company’s worldwide license for Mino-Lok™’s patented technology.
  • Completed Phase 2a studies for Hydro-Lido, which could become the first FDA-approved product to address the estimated $500M U.S. hemorrhoid marketplace.
We are extremely pleased with the significant advancements that we have made and the foundation for long-term growth that we have established,” stated Mr. Myron Holubiak, President and Chief Executive Officer of Citius Pharmaceuticals. “Having transitioned to a more senior exchange and completed key initiatives in advancing our unique technologies, we felt it necessary to provide a thorough update on the overall health and trajectory of the Company.  We are confident, now that we now well-funded, to ideally be positioned as potential market leaders in two greatly underserved therapeutic areas. Management is committed to advancing the commercialization efforts of our products, Mino-Lok™ and Hydro-Lido, while remaining focused on our goal of improving shareholder value.


Source: Yahoo Finance



CTXR announced it has received feedback from the U. S. Food and Drug Administration regarding amendments to the phase 3 study plan for Mino-Lok™, an adjunctive treatment for catheter related blood stream infection. There are currently no approved therapies to salvage infected central venous catheters (“CVCs”).  Citius is currently recruiting sites for a phase 3 trial of Mino-Lok in the United States.


The FDA stated that they recognized that there is an unmet medical need in salvaging infected catheters and agreed that an open label, superiority design would address the Company’s concerns and would be acceptable. They also reinforced their commitment to work with the Company to revise the trial design to meet the requirements of a new drug application.
Following the discussion with the FDA, Citius amended the phase 3 study design to remove the saline and heparin placebo control arm and to use an active control arm that conforms with today’s current standard of care. The Company also noted that the dwell times and dosing schedules of the antibiotic lock therapy (“ALT”) active control arm would be changed because there is an extreme level of variability and heterogeneity in how ALTs are dosed and used today.


Mr. Myron Holubiak, Chief Executive Officer of Citius, commented, “We are extremely pleased to work closely with the FDA to design a trial that meets today’s need for better information and evidence as it relates to the treatment of infected CVCs and dosing schedules for ALTs.  Experts agree that there is a great deal of variability allowed in the Infectious Disease Society of America (IDSA) guidelines with respect to the antibiotic chosen and the dwell times used for ALT’s.  We are confident that we will be able to demonstrate the superiority of our ready-to-use Mino-Lok over hospital compounded antibiotic solutions for which there have not been any largescale controlled studies or data driven evidence.



Below is the 3 month daily chart on CTXRCTXR has a support level in the $2.60 area and has significant room to the upside. A break past the 20 SMA of $3.05 and then the 50 SMA of $3.13 could lead to a breakout in the near-term.


ctxr chart
Get started on your research now and learn more about Citius Pharmaceuticals (CTXR) from this recent Corporate Presentation on their website.



Stock Market Leader


Reminder: If you decide to trade, remember to always use limit orders to control the price you are willing to pay.


Follow us on Twitter @NasdaqAlerts1 for real time updates.


For Quicker Alerts Text Keyword “NASDAQ” to 24587 to Receive SMS Mobile Alerts!


Notice and Disclaimer-Please Read Carefully
We are engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by or an offer or solicitation to buy or sell any security. Neither the owner of nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. Third parties and/or affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. has been compensated seventeen thousand five hundred dollars by a third party(TSX Ventures LLC) for this investor awareness campaign regarding CTXR. Any compensation received constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company​.​​​​​​​
Notice of Stock Price Movements and Volatility. Viewers of this newsletter should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week. Some of the content in this release contains forward-looking information within the meaning of Section 27 A of the Securities Act of 1 993 and Section 21 E of the Securities Exchange Act of 1 934 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1 995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) and the Financial Industry Regulatory Authority (“FINRA”) website Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Network has no obligation to update any of the information provided. its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our release or on our website may not have approved certain or any statements within the encourages viewers to supplement the information obtained from this release and our website with independent research and other professional advice. The content in this release is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. This release may provide hyperlinks to third party websites or access to third party content., its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does control, endorse, or guarantee any content found in such sites. By accessing, viewing, or using the website or communications originating from this release, you agree that, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website is at your sole risk. disclaims all warranties of any kind, express or implied. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at and filings made by public companies can be viewed at and/or then FINRA at: . In addition, FINRA has published information at its website on how to invest carefully
Questions regarding any information contained in this report may be sent to To review’s website and its disclaimer, please visit